|
Sep 10
|
Can Celcuity (CELC) Climb 87.59% to Reach the Level Wall Street Analysts Expect?
|
|
Aug 7
|
Celcuity Inc. Schedules Release of Second Quarter 2024 Financial Results and Webcast/Conference Call
|
|
May 30
|
Celcuity Announces Pricing of Underwritten Common Stock Offering
|
|
May 30
|
Celcuity Inc. Announces Plan to Initiate a Phase 3 Clinical Trial for Gedatolisib as First-Line Treatment for HR+/HER2- Advanced Breast Cancer and Secures Approximately $62 Million Debt Financing
|
|
May 15
|
Celcuity Inc. Reports First Quarter Financial Results and Provides Corporate Update
|
|
May 8
|
Celcuity Inc. Schedules Release of First Quarter 2024 Financial Results and Webcast/Conference Call
|
|
Apr 4
|
Celcuity To Present at Upcoming Needham and Stifel Investor Conferences
|
|
Apr 3
|
Celcuity Gains 12%, Insider Trades Reap Benefit
|
|
Apr 1
|
Celcuity Inc. (NASDAQ:CELC) Q4 2023 Earnings Call Transcript
|
|
Mar 28
|
Q4 2023 Celcuity Inc Earnings Call
|
|
Mar 27
|
Celcuity Inc (CELC) Reports Full Year 2023 Financial Results and Highlights Key Developments
|
|
Mar 27
|
Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
|
|
Mar 21
|
Why Celcuity (CELC) Might Surprise This Earnings Season
|
|
Mar 20
|
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Webcast/Conference Call
|
|
Mar 6
|
Celcuity to Participate in Leerink Partners Global Biopharma Conference 2024
|
|
Dec 6
|
Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer Symposium
|
|
Dec 1
|
Celcuity to Present Preclinical Data for Gedatolisib at the 2023 San Antonio Breast Cancer Symposium
|